Nghĩa của từ pharmaceutically bằng Tiếng Anh
adverb
via drugs and medications, medicinally
Đặt câu với từ "pharmaceutically"
1. The compositions are pharmaceutically acceptable injectable formulations which include an active component in a pharmaceutically acceptable carrier.
2. Pharmaceutically active insulin receptor-modulating molecules
3. Disclosed is a pharmaceutical composition comprising tranilast or a pharmaceutically acceptable salt thereof and allopurinol or a pharmaceutically acceptable salt thereof, wherein the amount by weight of said allopurinol or pharmaceutically acceptable salt thereof in said composition is greater than the amount by weight of said tranilast or pharmaceutically acceptable salt thereof in said composition.
4. Therefore, the acid addition salt can be useful as a pharmaceutically acceptable salt.
5. Pharmaceutical dosage forms comprising ecopipam free base or pharmaceutically acceptable salts thereof
6. Triazanonane derivative or pharmaceutically acceptable salt thereof for enhanced fluorine-18 labeling
7. Compounds of formula (I) and the pharmaceutically acceptable acid addition salts thereof, wherein R¿1?
8. Process for the preparation of pharmaceutically acceptable salts of (ss-rs)-s-adenosyl-l-methionine
9. The invention also discloses the preparation process and use of the toosendanin derivative having formula (II) and its pharmaceutically acceptable salts, the toosendanin derivative and its pharmaceutically acceptable salts have good treatment effects for botulinicum Antitoxinum animals.
10. The base may additionally comprise an acid sensitive or an alkali-sensitive pharmaceutically active substance.
11. Specifically disclosed is a compound represented by formula (I) or a pharmaceutically acceptable salt thereof.
12. Novel compound or pharmaceutically acceptable salt thereof, and pharmaceutical composition containing same as active ingredient
13. Pharmaceutical composition capable of readily controlling dissolution pattern of lacosamide or pharmaceutically acceptable salt thereof
14. The invention also provides pharmaceutically acceptable compositions of therapeutically effective amounts of furin endoprotease inhibitors.
15. Amidopyridinol derivative or pharmaceutically acceptable salt thereof and pharmaceutical composition comprising same as active component
16. Basidiomycete fungi are an attractive resource for biologically active natural products for use in pharmaceutically relevant compounds
17. Novel method for the synthesis of ivabradine and the addition salts thereof with a pharmaceutically acceptable acid
18. Claimed are compound srepresented by Formula II, its enantiomers, diastereoisomers, tautomers, or a pharmaceutically acceptable salt thereof.
19. The present invention relates to a 2-ethoxy benzoic acid derivative and a pharmaceutically tolerable salt thereof.
20. The present product can be used as material for the preparation of pharmaceutically acceptable pharmaceutical preparations.
21. Specifically disclosed is a compound represented by formula (1) or a pharmaceutically acceptable salt thereof.
22. Cyanoguanidine compounds of Formula (I) and their pharmaceutically acceptable acid addition salts where R¿1?
23. Both therapeutic agents and diagnostic agents can be used as pharmaceutically active substances for encapsulation.
24. Specifically provided is a phenyltriazole derivative represented by formula (I) or a pharmaceutically acceptable salt thereof.
25. The present invention relates to compounds of formula 1: and pharmaceutically acceptable acid addition sails thereof.
26. Within the cell culture chamber, the pharmaceutically active compound may be absorbed and transported by a cell monolayer.
27. Composition for preventing hair loss or promoting hair growth, containing oleanolic acid derivative and pharmaceutically acceptable salt thereof
28. Composition for preventing and treating asthma, containing benzofuran-based compound or pharmaceutically acceptable salt thereof as active ingredient
29. If desired, additional antimicrobial or other pharmaceutically active agents can also be incorporated into the hydrogel structure.
30. A method for manufacturing an injectable preparation of a pharmaceutically active agent for storage in the injection cartridge.
31. The present invention relates to new medical uses for ethylamino benzoic acid derivatives or pharmaceutically acceptable salts thereof.
32. Pharmaceutical composition for treatment of asthma containing 4-phenylbutyric acids or pharmaceutically acceptable salts thereof as active ingredient
33. Pharmaceutical composition for preventing or treating optic neuromyelitis comprising glycyrrhizic acid or pharmaceutically acceptable salt thereof as an active ingredient
34. Provided are: a dry syrup comprising a pharmaceutically active substance, starch and a thixotropic thickener; and a production method therefor.
35. The present invention relates to a matrix type pharmaceutical composition containing lacosamide, which is an active ingredient, or a pharmaceutically acceptable salt thereof.
36. The present invention relates to a C-kit activity inhibitor comprising carnosic acid, a derivative thereof or a pharmaceutically acceptable salt thereof.
37. The present invention relates to a skin irritation alleviation agent comprising carnosic acid, a derivative thereof or a pharmaceutically acceptable salt thereof.
38. A pharmaceutical formulation comprising:(1) a therapeutically effective amount of active nasal peptide, its pharmaceutically acceptable salt or its peptidic fragment; and (2) the absorbefacient and stabilizer THAM [tris(hydroxymethyl) aminomethane); in a pharmaceutically acceptable, aqueous liquid diluent or carrier, said formulation being in a form suitable for nasal administration.
39. The present invention relates to a novel adenine derivative and a pharmaceutical use thereof and, more specifically, to a novel adenine derivative having a structure of chemical formula 1 or a pharmaceutically acceptable salt thereof and to a composition for preventing or treating degenerative brain disease, the composition containing the novel adenine derivative or the pharmaceutically acceptable salt thereof.
40. The present invention also relates to a whitening composition or anti-ageing composition comprising a carnosic acid derivative or a pharmaceutically acceptable salt thereof.
41. Prostaglandin F2α (PGF2α in prostanoid nomenclature), pharmaceutically termed dinoprost (INN), is a naturally occurring prostaglandin used in medicine to induce labor and as an abortifacient.
42. The present invention relates to a novel benzamide compound functioning as an inverse agonist or an antagonist of a cannabinoid receptor (CB1), or pharmaceutically acceptable salts thereof.
43. A lidocaine-containing Cataplasm comprising a backing layer and an adhesive agent (plaster) layer laminated on the surface of the backing layer, wherein the adhesive agent (plaster) layer contains at least one component selected from the group consisting of lidocaine and pharmaceutically acceptable salts thereof, the total content of lidocaine and the pharmaceutically acceptable salts thereof
44. Novel disubstituted adamantyl derivative or pharmaceutically acceptable salt thereof, production method for same, and pharmaceutical composition for suppressing cancer metastasis comprising same as active ingredient
45. The present invention relates to a pharmaceutical composition that enables easy control of a release pattern of galantamine or pharmaceutically acceptable salts thereof as an active ingredient.
46. The invention concerns the use of riluzole or one of its pharmaceutically acceptable salts for preventing and/or treating acoustic traumas and, in particular, different types of deafness and tinnitus.
47. Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette ('ABC') transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator ('CFTR').
48. The invention concerns benzamide compounds of Formula (I), or a pharmaceutically acceptable salt thereof, where R1, ring A, n, R3, and R4 are as defined in the description.
49. According to the present invention, there are provided ethacrynic acid, a transglutaminase inhibitor comprising active components of a pharmaceutically acceptable salt of ethacrynic acid and a transglutaminase inhibition method.
50. The subject invention relates to methods for sebum control and treatment of acne in mammalian skin and scalp comprising administration of hesperetin, having structure (I) or a pharmaceutically acceptable salt thereof.